ID   MP41
AC   CVCL_4D12
DR   ATCC; CRL-3297
DR   cancercelllines; CVCL_4D12
DR   ChEMBL-Cells; CHEMBL4879544
DR   Wikidata; Q54906429
RX   PubMed=24994677;
CC   Characteristics: Established from a patient-derived xenograft.
CC   Doubling time: 41 hours (PubMed=24994677).
CC   Sequence variation: Mutation; HGNC; HGNC:4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=24994677).
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): ATCC=CRL-3297; PubMed=24994677
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 11,14
ST   D16S539: 13
ST   D21S11: 30.2,31.2
ST   D5S818: 10,13
ST   D7S820: 8.3,9,9.3,10,10.1,11 (ATCC=CRL-3297)
ST   D7S820: 9,10 (PubMed=24994677)
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 15,18
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   49Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 19-12-24; Version: 12
//
RX   PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004; PMCID=PMC5528590;
RA   Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A.,
RA   Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N.,
RA   Piperno-Neumann S., Mariani P., Sastre-Garau X., Decaudin D.,
RA   Roman-Roman S.;
RT   "Establishment of novel cell lines recapitulating the genetic
RT   landscape of uveal melanoma and preclinical validation of mTOR as a
RT   therapeutic target.";
RL   Mol. Oncol. 8:1508-1520(2014).
//